The India HPV-vaccine suspension

Larson, Heidi; Brocard, Pauline; Garnett, Geoffrey P.

doi:10.1016/s0140-6736(10)60881-1

Cited by 76 publications

(52 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also imperative to document the population-level impact of the HPV vaccine on disease reduction which can be difficult due to the long time window between vaccine introduction initially in adolescents and the peak ages for which HPV-related pre-cancers are detected. Limited data infrastructure, such as poor local epidemiological data, the absence of vaccination registries, and the inability to link relevant data, can hinder timely evidence-based assessments of vaccine effectiveness as well as responses to vaccine scares which has occasionally led to decisions to suspend vaccination such as in Japan [31] and India [32]. Finally, in some countries the lack of vaccine advocates and the social taboo of sexuality in adolescent girls have impeded communication related to HPV risk and vaccine awareness.…”

Section: Hpv Vaccination Program Weaknessesmentioning

confidence: 99%

Overcoming barriers in HPV vaccination and screening programs

Vorsters

Arbyn

Baay³

et al. 2017

Papillomavirus Research

View full text Add to dashboard Cite

A B S T R A C TThe Human Papillomavirus Prevention and Control Board brought together experts to discuss optimizing HPV vaccination and screening programs.Board members reviewed the safety profile of licensed HPV vaccines based on clinical and post-marketing data, reaching a consensus that current safety data is reassuring.Successful vaccination programs used well-coordinated communication campaigns, integrating (social) media to spread awareness. Communication of evidence supporting vaccine effectiveness had beneficial effects on the perception of the vaccine. However, anti-vaccination campaigns have threatened existing programs in many countries.Measurement and monitoring of HPV vaccine confidence over time could help understand the nature and scale of waning confidence, define issues and intervene appropriately using context-specific evidence-based strategies. Finally, a broad group of stakeholders, such as teachers, health care providers and the media should also be provided with accurate information and training to help support prevention efforts through enhanced understanding of the risks and benefits of vaccination.Similarly, while cervical cancer screening through population-based programs is highly effective, barriers to screening exist: awareness in countries with population-based screening programs, access for vulnerable populations, and access and affordability in low-and middle-income countries. Integration of primary and secondary prevention has the potential to accelerate the decrease in cervical cancer incidence. IntroductionThe HPV Prevention and Control Board was created in December 2015 [1] with the aim to share relevant information on HPV with a broad array of stakeholders, and to implement preventive strategies to reduce the HPV-related disease burden. Here we report the discussion that took place during the first official meeting, held on June 27 and 28, 2016, in Antwerp, Belgium.1The objectives of the meeting were (a) to summarize the available adverse event profile and any reported safety concerns following HPV vaccination, (b) to summarize cultural, perceptual, infrastructural and financial barriers to the implementation of vaccination, (c) to identify factors that influence adherence to cervical screening programs, (d) to propose strategies to build public confidence in HPV prevention programs and address any vaccination and screening hesitancy, and (e) to discuss new approaches to improve HPV prevention and cervical cancer control. Vaccine safety profileThe safety of new products is critical for licensure and successful implementation/uptake. Critical review of clinical trial data is the first step in this process. However, as clinical trials generally involve limited numbers, and participants may have health conditions different from those in the general population, post-marketing surveillance is essential.While licensure has varied according to country, HPV vaccines have been available since 2006 beginning with the quadrivalent (4vHPV, Gardasil, Merck), followed by the bivalent (2vHP...

show abstract

Section: Hpv Vaccination Program Weaknessesmentioning

confidence: 99%

Overcoming barriers in HPV vaccination and screening programs

Vorsters

Arbyn

Baay³

et al. 2017

Papillomavirus Research

View full text Add to dashboard Cite

show abstract

“…41,42 Despite these achievements in India, adverse events were falsely linked to the vaccine and the demonstration project was incorrectly characterized as an experimental clinical trial. 72,73 77,78 Findings from demonstration and national programs highlight the importance of incorporating community outreach and sensitization to the successful implementation of the HPV vaccine in LMICs.…”

Section: Community Outreach Approachesmentioning

confidence: 99%

Global Delivery of Human Papillomavirus Vaccines

Wigle

Fontenot

Zimet

2016

Pediatric Clinics of North America

View full text Add to dashboard Cite

• School-based approaches to HPV vaccine delivery have generally been very successful in both LMICs and high-income countries.• Clinic-or office-based delivery strategies have been evaluated, with some countries showing limited success (e.g., the U.S.) and others having greater success (e.g., Denmark).• Community outreach approaches have shown some success in HPV vaccine uptake, particularly in reaching children not in school P a g e | 3

show abstract

“…For instance, India suspended HPV vaccination demonstration projects because of public distrust in the vaccine Copyright 2015 KEI Journals. All Rights Reserved 6 | P a g e (Larson, Brocard, & Garnett, 2010). Japan suspended its recommendation that healthy young adolescent girls should all receive the series of three prophylactic HPV vaccination shots following negative media reports regarding purported serious but rare adverse side effects (Ueda et al, 2015).…”

Section: Governmental Concerns For Hpv Vaccine Programsmentioning

confidence: 99%

Working Towards Universal Implementation of Human Papillomavirus Vaccination to Prevent Cervical Cancer

Goodman

Joseph

2015

MRAJ

View full text Add to dashboard Cite

Human Papillomavirus (HPV) vaccination should be included in national immunization programs, as part of a comprehensive approach to cervical cancer prevention and control. The practical aspects of vaccine uptake are now the most important issue in HPV vaccine research from a public-health perspective. Increasing uptake, specifically in regions where disease burden is highest, will require thoughtful consideration of cost-effectiveness, innovative financing mechanisms, novel approaches to vaccine vehicle delivery and public acceptance. We review ongoing critical barriers and challenges to implementation of HPV vaccination. The aim of this paper is to review ongoing critical barriers and challenges to implementation of HPV vaccination.

show abstract

The India HPV-vaccine suspension

Cited by 76 publications

References 2 publications

Overcoming barriers in HPV vaccination and screening programs

Overcoming barriers in HPV vaccination and screening programs

Global Delivery of Human Papillomavirus Vaccines

Working Towards Universal Implementation of Human Papillomavirus Vaccination to Prevent Cervical Cancer

Contact Info

Product

Resources

About